US FDA's Breakthrough Program Needs Higher Standard For Comparators, NEJM Says

Harvard Medical School researchers call for inclusion of off-label drugs, accelerated approvals, and dietary supplements in the definition of 'existing therapies.'

SC1802_Lego Wall_658035112_1200.jpg

Three Harvard Medical School researchers are calling for the US FDA to broaden the definition of "existing therapies" in the criteria for the breakthrough therapy designation to raise the comparison baseline and increase the bar to qualify for the designation.

In a study published in the New England Journal of Medicine (NEJM) on April 11 that examines the first four...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet